Navigation Links
Vasogen Provides an Update on ACCLAIM-II Preparations
Date:12/17/2007

MISSISSAUGA, ON, Dec. 17 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ:VSGN; TSX:VAS) today provided an update on ACCLAIM-II, a confirmatory clinical trial which is designed to support an application for US market approval of the Celacade(TM) System for the treatment of patients with NYHA Class II heart failure.

The Company has been working diligently on the ACCLAIM-II study, including the establishment of a Steering Committee led by James B. Young, MD, Chairman, Division of Medicine at the Cleveland Clinic Foundation and Medical Director, Kaufman Center for Heart Failure; appointing Chairs for the Data and Safety Monitoring Board (DSMB) and Central Endpoint Committee (CEC); developing the study protocol, CEC adjudication plans, and other key trial documents, such as case report forms and informed consent forms; and selecting a contract research organization to assist with study execution.

Concurrent with the preparations for ACCLAIM-II, Vasogen has been working closely with the U.S. Food and Drug Administration (FDA) to finalize the protocol and the statistical analysis plan for the study using a Bayesian approach and adaptive clinical design. The planned study design indicates that as few as 300 patients could provide sufficient data to confirm the finding in the pre-specified sub-group of ACCLAIM patients with NYHA Class II heart failure. Furthermore, the use of an adaptive clinical trial design also provides the flexibility to increase the sample size up to 600 patients, should additional data be required. The ACCLAIM trial demonstrated a 39% reduction (p=0.0003) in the risk of death and cardiovascular hospitalizations for the large pre-specified subgroup of 689 NYHA class II heart failure patients.

In preparation
'/>"/>

SOURCE Vasogen Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. CardioDynamics Provides 2007 Shareholder Meeting Update
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. NxStage Medical Provides Update on Medisystems Acquisition
7. VaxGen Files 2006 Financial Statements and Provides Cash Update
8. Signalife Provides Corporate Update
9. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
10. Elekta Contract Provides Sisters of Mercy Health System Access to Leading Radiation Therapy Solutions
11. SGX Provides Update on BCR-ABL Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014 LayerBio, Inc., an MIT spinoff ... first round of seed financing from friends and family ... to develop a novel sustained-release product for ophthalmology. , ... and their commitment to this important work," said Dr. ... one of many areas in which innovations in drug ...
(Date:7/29/2014)... technologists have hurdled a number of significant technological ... revolutionary observing technology originally created for the James ... Principal Investigator Harvey Moseley, a scientist at NASA,s ... demonstrated that electrostatically actuated microshutter arrays that ... are as functional as the current technology,s ...
(Date:7/29/2014)... 2014 Human Longevity, Inc. (HLI), a genomics ... extending the healthy, high performance human life span, today ... an expert in machine learning and machine translation as ... from Google where he was Distinguished Research Scientist and ... to HLI Co-Founder and CEO, J. Craig Venter ...
(Date:7/29/2014)... a new way of manufacturing microstructured surfaces that ... self-assembly of carbon nanotubes, could exhibit a variety ... and strength, or the ability to repel water ... that mechanical forces can be used to direct ... we can independently control the mechanical properties ...
Breaking Biology Technology:Revolutionary microshutter technology hurdles significant challenges 2Revolutionary microshutter technology hurdles significant challenges 3Revolutionary microshutter technology hurdles significant challenges 4Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 2Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 3A new way to make microstructured surfaces 2
... COLUMBIA, Md., Oct. 16 Martek announced today,that ... of the former,stockholders of OmegaTech in ongoing litigation ... included in the,April 2002 merger agreement. In connection ... Martek common stock to the former stockholders of,OmegaTech, ...
... Bioponic,Phytoceuticals, Inc. (OTC: BPYT) ("Bioponic"), an ... serving the Complementary,Alternative Medicine (CAM) and nutraceutical ... Sales and Marketing of Southern California as ... including the states,of California, Washington, Nevada, Arizona, ...
... Full Range of Fertility Services and Surgeries, ... Dr. John Jain, a,fertility specialist with one ... announced today the grand opening of Santa ... health center in Santa,Monica, California. The center ...
Cached Biology Technology:Martek Announces Settlement of OmegaTech Milestone Litigation 2Bioponic Phytoceuticals to Roll Out Multiple Products to 1,000 Major Health Food Stores in the Western United States 2Pioneer in Reproductive Medicine Opens The Country's First Comprehensive Fertility Practice 2
(Date:7/28/2014)... United States have a circulatory problem of the legs ... may even require surgery in serious cases. This disease ... turn, limb amputation. , At The University of Texas ... tested a non-surgical preventative treatment in a mouse model ... blood circulation. Their proof-of-concept study appears in the ...
(Date:7/28/2014)... Fifteen years ago, MIT professor John Essigmann and colleagues from ... HIV drug. They thought if they could induce the virus ... eventually die out a strategy that our immune system ... a drug, which caused HIV to mutate at an enhanced ... from patients in a small clinical trial reported in 2011. ...
(Date:7/28/2014)... rat brain cells suggests that the effects of a ... cells are temporary. , The study, published in this ... was conducted by biologists at the University of California, ... York in response to concerns, arising from multiple studies ... to general anesthetics may increase their susceptibility to long-term ...
Breaking Biology News(10 mins):Scientists discover genetic switch that can prevent peripheral vascular disease in mice 2Forced mutations doom HIV 2Forced mutations doom HIV 3Forced mutations doom HIV 4Study suggests disruptive effects of anesthesia on brain cell connections are temporary 2Study suggests disruptive effects of anesthesia on brain cell connections are temporary 3
... have made a discovery that may explain how prion diseases, ... order to spread between various types of animals., The research ... change in the prions, makeup appears to give the disease ... strains with which it comes into contact. The team has ...
... what they eat, and whether horse meat might have ... headlines globally - calling for new policies in ... identification and authentication. As companies and manufacturers resort to ... public, it is estimated that up to 7% of ...
... March 11, 2013  Wake Forest Baptist Medical Center ... commercialization enterprise, Wake Forest Innovations, as well as ... Wake Forest Innovation Quarter After consultation ... and an analysis of park names worldwide, Piedmont ...
Cached Biology News:Discovery may explain how prion diseases spread between different types of animals 2DNA barcoding alone sufficient to detect fraudulent deer products 2DNA barcoding alone sufficient to detect fraudulent deer products 3Wake Forest Innovations Launches New Dot-Com Companies Offering Industry and Business Easy Access to Broad Range of Scientific Services 2Wake Forest Innovations Launches New Dot-Com Companies Offering Industry and Business Easy Access to Broad Range of Scientific Services 3Wake Forest Innovations Launches New Dot-Com Companies Offering Industry and Business Easy Access to Broad Range of Scientific Services 4Wake Forest Innovations Launches New Dot-Com Companies Offering Industry and Business Easy Access to Broad Range of Scientific Services 5
Designed for use with the Agencourt CleanSEQ and Agencourt AMPure 384-well SPRI reagent kits. For use with 384-well thermal cycling plates....
... Removal , , Removes ... cross-reactivity with other proteins , Simple, just ... Economical new surface technology, not based on ... with protein analysis. SurfactAway offers a simple ...
... SDS and Non-ionic Detergent Removal ... , Very selective, virtually no cross-reactivity with ... and discard pellet , Economical new ... , Detergents can often interfere with protein ...
... 3000 workstation automates a wide array of ... Proteomic Sample Preparation to Bio-Molecular and Cell ... of the Caliper Sciclone enables numerous combinations ... meet the needs of a given application, ...
Biology Products: